Short answer
Zenas BioPharma, Inc. (ZBIO) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $10M with net income of −$109M.
Q3 2026 key financials · XBRL
- Revenue
- $10M
- Net income
- −$109M
- −111.5% YoY · +2.3% QoQ
- Operating margin
- -1034.1%
- EPS (diluted)
- −$1.67
- −36.9% YoY · +6.2% QoQ
Source: XBRL data from the Zenas BioPharma, Inc. (ZBIO) Q3 2026 10-Q on SEC EDGAR. USD.
Zenas BioPharma, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $10.0M, up from $0, driven by BMS development and regulatory milestone
- Net loss $108.9M vs $51.5M YoY, operating margin -1,034.1% vs not meaningful
- R&D $58.5M, led by obexelimab $22.6M and orelabrutinib $12.9M
- Cash, equivalents and investments $647.1M, operating cash outflow $190.4M for nine months
- Outlook: cash runway into 2029, with SLE topline results expected Q4 2026 and tariff-related cost headwinds
Risk Factors
- New regulatory risk: April 2026 U.S. tariffs on patented pharmaceutical products, potentially increasing imported obexelimab costs
- China supply-chain exposure: WuXi Biologics remains sole obexelimab CMO, with imports subject to existing tariffs
- Debt-servicing risk: Operations are not expected to generate sufficient cash flow to service debt and fund capital expenditures
- Convertible-note liquidity risk: Required cash settlements upon conversion could materially reduce liquidity
- Maturity risk: Loan Agreement matures in 2031, requiring refinancing or repayment capacity then
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Zenas BioPharma, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.